文献速递间质性肺疾病

IPF成纤维细胞中PGC1α受抑驱动病理性代谢、分泌与纤维化状态

PGC1α repression in IPF fibroblasts drives a pathologic metabolic, secretory and fibrogenic state.
PubMed 文献 · Thorax · 2019-06-10

研究探讨线粒体生物合成主调控因子PGC1α在特发性肺纤维化(IPF)中是否降低并控制病理性成纤维细胞活化。结果显示IPF成纤维细胞中PGC1α稳定受抑,敲低正常成纤维细胞PGC1α可降低线粒体质量与功能并增强纤维化活化,而在IPF成纤维细胞中恢复PGC1α可改善这些病理功能;罗格列酮可升高PGC1α表达并减轻成纤维细胞活化。

要点

  • IPF成纤维细胞中PGC1α表达稳定受抑,与线粒体质量及功能下降相关。
  • 敲低PGC1α足以增强正常肺成纤维细胞的收缩、基质合成与衰老相关分泌。
  • 恢复PGC1α或罗格列酮处理可减轻IPF成纤维细胞的病理活化。

核心结论

  • PGC1α持续受抑是IPF成纤维细胞病理状态的重要调控环节,恢复其表达可改善多种病理细胞功能。

研究设计与样本

  • 使用原代人IPF与对照肺成纤维细胞,以及博来霉素损伤小鼠中分选的成纤维细胞评估PGC1α表达与功能。
  • 体外通过小干扰RNA敲低或过表达操作PGC1α;用定量PCR、Western blotting、基质沉积、分泌细胞因子芯片、免疫荧光与牵引力显微镜评估成纤维细胞活化。
  • 用Seahorse分析仪评估线粒体功能,用流式细胞术、线粒体DNA定量与透射电镜评估线粒体质量与数量。

主要发现

  • IPF成纤维细胞中PGC1α水平稳定受抑。
  • 年轻小鼠博来霉素损伤后PGC1α表达短暂下降,随后在纤维化消退前回升;老年小鼠持续纤维化时PGC1α表达未能恢复。
  • 正常 human 肺成纤维细胞中敲低PGC1α降低线粒体质量与功能,同时增强收缩与基质合成性活化、衰老相关基因表达及可溶性促纤维化与促衰老信号。
  • 在IPF成纤维细胞中重新表达PGC1α可改善上述全部病理细胞功能。
  • 罗格列酮(而非甲状腺激素)处理IPF成纤维细胞可升高PGC1α表达并减轻成纤维细胞活化。

临床怎么用

  • PGC1α可作为IPF成纤维细胞病理状态的潜在调控靶点。
  • 罗格列酮在体外可升高IPF成纤维细胞PGC1α表达并减轻活化,提示药物干预线粒体生物合成途径的可能性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Idiopathic pulmonary fibrosis (IPF) is a fatal ageing-related disease linked to mitochondrial dysfunction. The present study aimed to determine whether peroxisome proliferator activated receptor gamma co-activator 1-alpha (PPARGC1A, encoding PGC1α), a master regulator of mitochondrial biogenesis, is diminished in IPF and controls pathologic fibroblast activation. Primary human IPF, control lung fibroblasts and fibroblasts sorted from bleomycin-injured mice were used to evaluate the expression and function of PGC1α. In vitro PGC1α manipulation was performed by small interfering RNA knockdown or overexpression. Fibroblast activation was assessed by quantitative PCR, Western blotting, matrix deposition, secreted cytokine array, immunofluorescence and traction force microscopy. Mitochondrial function was assessed by Seahorse analyzer and mitochondria mass and number by flow cytometry, mitochondrial DNA quantification and transmission electron microscopy (TEM). We found that PGC1α levels are stably repressed in IPF fibroblasts. After bleomycin injury in young mice, PGC1α expression drops transiently but then increases prior to fibrosis resolution. In contrast, PGC1α expression fails to recover in aged mice with persistent fibrosis. PGC1α knockdown alone in normal human lung fibroblasts reduces mitochondrial mass and function while enhancing contractile and matrix synthetic fibroblast activation, senescence-related gene expression and soluble profibrotic and prosenescence signalling. Re-expression of PGC1α in IPF fibroblasts ameliorates all of these pathological cellular functions. Pharmacological treatment of IPF fibroblasts with rosiglitazone, but not thyroid hormone, elevated PGC1α expression and attenuated fibroblast activation. The sustained repression of PGC1α and beneficial effects of its rescue in IPF fibroblasts identifies PGC1α as an important regulator of the fibroblast's pathological state in IPF.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Caporarello N, Meridew JA, Jones DL, et al. PGC1α repression in IPF fibroblasts drives a pathologic metabolic, secretory and fibrogenic state. Thorax. 2019. PMID: 31182654. doi:10.1136/thoraxjnl-2019-213064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。